Patents by Inventor David Weiner

David Weiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VACCINES AGAINST AFRICAN SWINE FEVER VIRUS, AND METHODS OF USING SAME
    Publication number: 20230256074
    Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing at least one African swine fever virus (ASFV) antigen that elicits an immune response in a mammal against ASFV virus, and methods of use thereof.
    Type: Application
    Filed: December 21, 2020
    Publication date: August 17, 2023
    Inventors: Kar Muthumani, David Weiner
  • CORONAVIRUS DISEASE 2019 (COVID-19) COMBINATION VACCINE
    Publication number: 20230210981
    Abstract: Disclosed herein is a vaccine comprising a Coronavirus disease 2019 (COVID-19) antigen in a combination with an immunoglobulin from post-exposure treatment. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
    Type: Application
    Filed: June 9, 2021
    Publication date: July 6, 2023
    Inventors: David Weiner, Ami Patel
  • DNA ANTIBODY CONSTRUCTS FOR USE AGAINST SARS-COV-2
    Publication number: 20230212267
    Abstract: Disclosed herein are antibodies to SARS-CoV-2 antigens and recombinant nucleic acid sequences that encode the SARS-CoV-2 antibodies. The disclosure also provides a method of preventing and/or treating a SARS-CoV-2 infection or disease or disorder associated with SARS-CoV-2 infection (e.g., COVID-19) in a subject using said compositions and methods.
    Type: Application
    Filed: June 9, 2021
    Publication date: July 6, 2023
    Inventors: David Weiner, Elizabeth Parzych, Kar Muthumani
  • DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HEPATITIS B VIRUS
    Publication number: 20230203133
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Hepatitis B viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Hepatitis B virus infection in a subject using said composition and method of generation.
    Type: Application
    Filed: May 6, 2021
    Publication date: June 29, 2023
    Inventors: Kar Muthumani, David Weiner
  • Vaccines against coronavirus and methods of use
    Patent number: 11660335
    Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: May 30, 2023
    Assignees: Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
    Inventors: Jian Yan, Kate Broderick, David Weiner, Kar Muthumani, Ami Patel
  • ENGINEERED OPTIMIZED CYTOKINE COMPOSITIONS
    Publication number: 20230159602
    Abstract: The present invention relates to recombinant optimized polynucleotide encoding a cytokine or cytokine receptor and to methods of making a recombinant optimized polynucleotide encoding a cytokine or cytokine receptor.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 25, 2023
    Inventors: Rajasekharan Somasundaram, Kar Muthumani, David Weiner
  • Vaccines against zika virus
    Patent number: 11648303
    Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: May 16, 2023
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
    Inventors: David Weiner, Kar Muthumani
  • TERT IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME
    Publication number: 20230115179
    Abstract: Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.
    Type: Application
    Filed: October 11, 2022
    Publication date: April 13, 2023
    Inventors: David Weiner, Jian Yan
  • Marburgvirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
    Patent number: 11596678
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 7, 2023
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomv and Biologv
    Inventors: David Weiner, Ami Patel, Sarah Elliott
  • CD40-L BLOCKADE TO ENHANCE SYNTHETIC ANTIBODY THERAPY
    Publication number: 20230063151
    Abstract: Disclosed herein are combinations of inhibitors of B cell maturation and recombinant nucleic acid molecules encoding synthethic antibodies, and their use for extending the duration of circulating synthetic antibodies and for treating diseases and disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: March 2, 2023
    Inventors: David Weiner, Ami Patel, Alfredo Perales-Puchalt, Megan C. Wise, Sarah T.C. Elliott
  • Vaccines Against Coronavirus and Methods of Use
    Publication number: 20220370598
    Abstract: Provided herein are methods of inducing an immune response against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof by administering an immunogenic composition to the subject, wherein the subject exhibits: an increase in antigen-specific cellular immune response as measured by Interferon-gamma (IFN-?) Enzyme-linked Immunospot (ELISpot) assay relative to baseline; and/or an increase in neutralizing antibody response as measured by a pseudovirus neutralizing assay relative to baseline.
    Type: Application
    Filed: May 5, 2022
    Publication date: November 24, 2022
    Inventors: Jian Yan, Kate Broderick, David Weiner, Kar Muthumani, Ami Patel
  • EPSTEIN-BARR VIRUS NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME
    Publication number: 20220354945
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Epstein-Barr virus (EBV) antigen. Immunomodulatory methods and methods of inducing an immune response against EBV are disclosed. Method of treating infection by EBV and methods of treating or preventing a disease or disorder associated with EBV are disclosed. Modified consensus EBV antigens are disclosed.
    Type: Application
    Filed: June 22, 2022
    Publication date: November 10, 2022
    Inventors: David Weiner, Alfredo Perales Puchalt
  • MULTIVALENT DNA ANTIBODY CONSTRUCTS AND USE THEREOF
    Publication number: 20220324948
    Abstract: Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including one or more recombinant nucleic acid sequence that encodes a synthetic antibody or synthetic multivalent antibody to the subject. The disclosure also provides a compositions and methods of preventing and/or treating a Neisseria gonorrhoeae infection in a subject using said synthetic antibody or synthetic multivalent antibody.
    Type: Application
    Filed: July 31, 2020
    Publication date: October 13, 2022
    Inventors: David Weiner, Elizabeth Parzych, Ami Patel
  • TERT immunogenic compositions and methods of treatment using the same
    Patent number: 11464841
    Abstract: Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 11, 2022
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
    Inventors: David Weiner, Jian Yan
  • MULTIVALENT DNA ANTIBODY CONSTRUCTS AND USE THEREOF
    Publication number: 20220275065
    Abstract: Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including a recombinant nucleic acid sequence that encodes an antibody, a synthetic antibody, or a synthetic multivalent antibody to a subject. The disclosure also provides compositions and methods of preventing and/or treating a bacterial infection in a subject using said antibody, synthetic antibody, or synthetic multivalent antibody.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 1, 2022
    Inventors: David Weiner, Ami Patel
  • Epstein-Barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same
    Patent number: 11395851
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Epstein-Barr virus (EBV) antigen. Immunomodulatory methods and methods of inducing an immune response against EBV are disclosed. Method of treating infection by EBV and methods of treating or preventing a disease or disorder associated with EBV are disclosed. Modified consensus EBV antigens are disclosed.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: July 26, 2022
    Assignee: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
    Inventors: David Weiner, Alfredo Perales Puchalt
  • COMPOSITIONS, COMPRISING IMPROVED IL-12 GENETIC CONSTRUCTS AND VACCINES, IMMUNOTHERAPEUTICS AND METHODS OF USING THE SAME
    Publication number: 20220193230
    Abstract: Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes IL-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes IL12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed. Method of modulating immune response and methods of inducing an immune response against an immunogen are disclosed. Therapeutic and prophylactic vaccination methods are also disclosed.
    Type: Application
    Filed: December 28, 2021
    Publication date: June 23, 2022
    Inventors: David Weiner, Matthew P. Morrow, Jian Yan
  • DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
    Publication number: 20220112271
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: David WEINER, Trevor RF SMITH, Kar MUTHUMANI
  • DNA Antibody Constructs And Method Of Using Same
    Publication number: 20220112273
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 14, 2022
    Inventors: David Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai
  • DNA-ENCODED BISPECIFIC T-CELL ENGAGERS TARGETING CANCER ANTIGENS AND METHODS OF USE IN CANCER THERAPUTICS
    Publication number: 20220098324
    Abstract: Disclosed herein are compositions comprising a recombinant nucleic acid sequence encoding a bispecific immune cell engaging antibody (DICE), a recombinant nucleic acid sequence encoding a bispecific T cell engaging (DBiTE) antibody, a fragment thereof, a variant thereof, or a combination thereof.
    Type: Application
    Filed: January 30, 2020
    Publication date: March 31, 2022
    Inventors: David Weiner, Alfredo Perales-Puchalt, Kar Muthumani, Elizabeth Duperret